Press release: dupixent® (dupilumab) approved by european commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis

Dupixent ® (dupilumab) a pproved by european commission as f irst and o nly t argeted m edicine for c hildren as y oung as s ix m onths o ld with s evere a topic d ermatitis

REGN Ratings Summary

REGN Quant Ranking